Member Info for BoNidel

Saw the bid moved up again earlier to 1.80, they were looking for around 5800 IIRC.

Now showing only 384 wanted.

You’d have thought the price would have moved more if there was genuine interest from a large investor or institution but then I suppose there simply isn’t the volume available currently for anyone to take a serious position.

Has anyone got any estimates on timescales involving the $10m IPO/offering/uplisting, and how long it will take before it’s priced?

I wonder if one II would be able to fill the entire offering for a major stake in Accustem?

Certainly interesting

Looking at old prices it was around 55 cents a share for the ACMSY ADRS.

Im not sure how that would reflect now and if there was actually dilution from the Tiziana placing (are they trade-able shares?) but that means the high off accustem in current prices (10/1 consolidation) would give an equivalent price of around $5-$5.50, so MCAP in the region of $50-$60m.

Still a far cry from the previous valuation of $280m

“ Research note by H.C.Wainwright & co:

“Accustem may be publicly listed upon completion of the spinout; its valuation could be fairly reckoned at $280M—10% of the valuation placed upon Genomic Health at the time of its acquisition by EXACT Sciences last year.”

But it will be interesting to see what happens from here.

Hopefully we get news soon. Would be great to see it perform really well and may re-instil some confidence from shareholders in Tiziana itself.

It was interesting today that the bid moved up to 1.75 and that they would take 10,000 at price yet by the looks of things they only managed to get a few thousand so obviously a lot of people aren’t overly keen on selling at 1.75

Looking at what the bid price has been, I would say that today around 7k shares were bought @ 1.90

Although it shows as closing “down”, that’s actually a decent day as not just a jump up. I would imagine GC is still buying, for which I am grateful. Let’s hope accustem comes good ASAP and maybe TLSA share price will increase if shareholders have been delivered value (restore faith in management).

I believe it was 29th July they did the confidential filing with the SEC so surely 4 months in would suggest a listing can’t be a million miles away

Indeed it does.

Does anyone have any idea how long before the uplifting is priced?

I have read that confidential IPO filings have to give at least 15 days notice before listing or doing a “road show”.

I wonder if we are the cusp here of something big with accustem.

If it’s anywhere near what it was supposed to be, the upside could be huge from this point. Certainly feels like we found the bottom.

No listing and no sentiment may have been a hell of an opportunity.

I have bought a fair few lately but to be honest, all it would do is get me out of the deep end with TILS and I would probably (stupidly) average down further with TILS if this did fly.

Granted there was a buy (by the looks) Maybe someone is dumping at low pre market prices. Hopefully a couple of buys @ around $0.62 again will stop it flying to 0!

Looks like someone is starting to dump on the Nasdaq pre-market

7k volume and down 20% today. I wonder how many more will be dumped before market opens.

Bought more recently, have been telling myself “surely it can’t go much lower) for 18 months now.

Let’s all pray that accustem isn’t just a load of baloney and gives us a fighting chance here.

Having re-watched the video posted yesterday, aren’t the sales of OncotypeDX somewhere in the region of $350m (according to GC).

Also, SPARE is the 2nd generation of stemprinter so may well be more accurate again.

There are other competitors in the market as well such as Mammaprint.

I can see the ask has moved to 2.43 now on the level 2 of OTC.

Maybe this is finally about to move.

Could do with some PR from the BOD to understand exactly what is happening and the plan moving forward. They have been in-situ around 6 months now, surely there are updates (aside from the patent issuance)

No, I would be really keen to know though as I have been consistently buying (blind gambling) for the past 12 months thinking that on the small chance it does actually do something, it must be worth a lot more than the 5-10m MCAP that has floated around which is a far cry from the supposedly conservative $280m valuation figure that was put on it 2 years ago (based on 10% of the exact sciences $2.8BN genomic health takeover which included on of the main products - “OncotypeDX” which StemprintER was shown to be 40% more effective than).

I’m sure oncotype Dx Somewhere was listed as having well in excess of $100m annual revenue now so surely Accustem has got be worth a years worth of Oncotype revenue, before they find any other uses for it!

growth on exact/oncotype sales seems to be really big year on year as well

Probably on its a**e unless GC decides to make a point and buy a ton. I think those of us that have continued averaging down may just have to sit and wait to find the very bottom. This is seriously seriously ugly, lot of holders down well over 90% over last few years. What I don’t understand is where the sells come from at these levels.

Maybe I’m a fool for holding and not cutting my losses but if you’re down £900 on every £1000, why bother selling. You’ve got nothing left anyway.

I bought a lot at different prices but it really does stink at the moment. I can’t see light at the end of the tunnel either, the sector hasn’t come back that much and the Mis-management and lack of comma has probably put some investors off for life

As I’m writing it you post the same thing! Buried good and proper

Conveniently the press release comes out when the market is closed and thanksgiving is the next day (so no trading).

GC, if you’re reading this & are serious about tils then you need to throw some more money at this.

Everyone says GC is invested here but what did the initial holding actually cost him?

Only GC really knows the true value of this and what’s really going on, and if he’s truly confident, maybe he could push us back over the $1 mark on the Nasdaq and establish a baseline.

I don’t know where we go from here. Every week it just gets worse. The bad management with the Nasdaq switch was obviously as bad as we thought.

I feel bad sometimes for constantly kicking this but you have to call a spade a spade.

Where is the plumber? What are his thoughts on this? Perhaps the BOD should have done their auditing work rather than meeting with individual shareholders.

For Christ sake, parish councils can pass an audit every year which is checked by a district auditor. What the HELL is going on.

Do they even have any cash left? Who knows what the hell is true or false now

“ the auditor for Tiziana Life Sciences Ltd. (the “Company”) resigned as auditor because in its opinion the Company no longer meets their acceptable risk criteria as, in its opinion, material weaknesses in controls over financial reporting had not been sufficiently remediated.”

Great, so I tried to further “average down” this past few weeks, looks like I’ve probably averaged up. They are maybe that incompetent, even their auditors have resigned.

What the hell is going on

I was also wondering about this.

So it was safe but didn’t work in vivo?..

Current MCAP is around £50m in sterling.

In 2019 (pre covid spike) it ranged from around £100m-£200m. When is our luck going to change here?

Granted we don’t have accustem any more but don’t we have around

$30m in cash still and surely Foralumab is now further along than it was 3 years ago…

Don’t know if it’s a good thing or bad now even!

Maybe he’s just trying to keep the price out of the gutter.

Come on GC, we haven’t heard anything from WB or the accustem team. Put your money where your mouth is and pump this price so we get a decent IPO valuation

I think Accustem price touched 1.30 yesterday. The bid was at least 1.15

It will be interesting to see if someone in particular was purchasing those or just open market.

WRT to the Tiziana SP, I seem to remember in the investor call that GC mentioned they have another 180 days to regain compliance. Naturally they can’t say wether there will be another reverse split, buyback or anything else to achieve that. I’m sure he mentioned they intend to meet that target.

I’m not sure but did they ever finish the $5m buyback?

I was furious with the lack of comms and contempt shown for shareholders by the BOD, especially with the LSE to NASDAQ only switch and issues with settlement of shares therein. That being said, whatever the plan to get back above $1, I suppose they can’t really advise where or when this may or may not happen as it just makes it an easy target to trade and sell if so!

I confess that as a glutton for punishment, I did buy a few more TLSA stock yesterday. To be fair, I am trying to get my head back out of water and hoping this is kind of “averaging down”, with a view to getting out of jail in the next year or two depending on the global situation with biotech and indeed TILS own progress.

At current levels, (forgive me if I’m wrong here) the current SP is around 55p sterling,

Pre consolidation (2 for 1), doesn’t that make the SP 27.5p in sterling? Or was that a further split after the NASDAQ only move, meaning the current relative SP for TILS equivalent shares (like 2020 era) would be in the region of 13.75p?

As a current LTH, I am still more interested in getting out of TILS after the terrible lack of comms etc but progress here with foralumab MS trials etc and spearheaded approach for FMAB does look encouraging.

I think GC probably already knew that biotech was going to suffer for a while, probably not to the levels we see here after the 2020 boom but I think it’s wise to try and generate serious interest and Proof of concept to drive the SP and then raise at sensible terms as opposed to going to venture capital or by placing at current levels. I suppose timing is everything, but market forces EG sector performance is out of control of anyone. You can have the best business in the world, but if the sector performs badly then the SP will reflect.

I just hope they have a plan now and are seriously, vigorously and actively pursuing the trials with FMAB and indeed spending the cash they raised for this purpose!

I have been nothing but critical of them since 2020 but do hope the recent call was sincere.

Going from a big profit (and holding) to a big loss (and holding) sure has been a lesson for me.

Maybe I will feel different depending on what FMAB shows in coming months. If it’s solid and attracts genuine market interest then I suppose the SP should get back somewhere more sensible and perhaps more importantly than that, stabilise to a consistent level.

Massive fingers crossed for accustem pric

MM’s looking to take 6000 @ 0.95 bid on accustem. Best price I’ve seen for a while on bid. Spread only 0.03cents.

Maybe it’s finally time for this to move

Does anyone have any idea yet on the dilution or pricing?

I’m hoping we get some updates from WB soon WRT to the other applications or whatever it was. Let’s hope the markets take interest in this now and pump the price for the IPO!